Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | GALR3 | O60755 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640127 | 0.87 | LMNA (0.67) | KMT2AMEN1LMNAMAPK1POLB | |
| SCHEMBL9710367 | 0.86 | KMT2A (0.62) | KMT2AMEN1LMNAMAPK1POLB | |
| SCHEMBL5639598 | 0.85 | LMNA (0.64) | KMT2AMEN1LMNAMAPK1POLB | |
| SCHEMBL5641073 | 0.85 | POLB (0.65) | KMT2AMEN1LMNAMAPK1POLB | |
| SCHEMBL14514323 | 0.82 | KMT2A (0.70) | KMT2AMEN1LMNAMAPK1NOD2 | |
| SCHEMBL10726989 | 0.82 | NPSR1 (0.64) | KMT2AMEN1LMNAPOLBNPC1 | |
| SCHEMBL5639255 | 0.81 | POLB (0.58) | KMT2AMEN1LMNAMAPK1POLB | |
| SCHEMBL10729777 | 0.79 | NOTUM (0.60) | KMT2AMEN1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL9722714 | 0.78 | RAB9A (0.64) | KMT2AMEN1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL31447799 | 0.77 | LMNA (1.00) | KMT2AMEN1LMNAMAPK1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | KMT2A 1473/4885MEN1 2126/4885LMNA 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.